Trilaciclib is a Small Molecule owned by G1 Therapeutics, and is involved in 23 clinical trials, of which 10 were completed, 9 are ongoing, and 4 are planned.

Trilaciclib inhibits cyclin-dependent kinase (CDK) 4/6. CDKs govern cell cycle progression and regulate cellular from transition from G1 (growth phase) to S (DNA replication) and G2 (growth phase) to M (mitosis). G1T28 acts by inhibiting cell-cycle progression from G1 to S phase, resulting in suppression of DNA replication and decreased tumor cell proliferation which results in cells that are more resistant to DNA damage. It inhibits retinoblastoma (Rb) protein phosphorylation in early G1 stage. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth.

The revenue for Trilaciclib is expected to reach a total of $2.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Trilaciclib NPV Report.

Trilaciclib is originated and owned by G1 Therapeutics. Simcere Pharmaceutical Group is the other company associated in development or marketing of Trilaciclib.

Trilaciclib Overview

Trilaciclib (Cosela) is a potential antineoplastic agent with chemoprotective properties. It is formulated as lyophilized cake for solution for intravenous route of administration. Cosela is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to  a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

Trilaciclib is under development for the treatment of small-cell lung cancer, metastatic bladder cancer (locally advanced or metastatic urothelial carcinoma), metastatic triple negative breast cancer, colon cancer, metastatic colorectal cancer, castrate-resistant prostate cancer, NSCLC as first line and chemotherapy-induced myelosuppression. It is administered through intravenous route. The drug candidate acts by targeting cyclin-dependent kinases (CDK) 4 and 6. It was also under development for the treatment of non-small cell lung cancer.

Simcere Pharmaceutical Group Overview

Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company’s precision medicine sector, Simcere diagnostics had strategic partnership t with Agena bioscience focused on Agena’s Massarray System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China

The company reported revenues of (Renminbi) CNY4,999.7 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 29%, compared to an operating margin of 20.6% in FY2020. In FY2021, the company recorded a net margin of 30.1%, compared to a net margin of 14.8% in FY2020.

Quick View – Trilaciclib

Report Segments
  • Innovator (NME)
Drug Name
  • Trilaciclib
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.